Evotec to acquire cell technology firm Rigenerand
The deal will add the Evotec EVOcells cell therapy platform to Rigenerand’s cGMP manufacturing site.

The deal will add the Evotec EVOcells cell therapy platform to Rigenerand’s cGMP manufacturing site.
EUSA Pharma’s product portfolio includes Qarziba, Sylvant, Fotivda and Caphosol.
The dosage for children is indicated to be a third of the authorised 30µg dose given to adults and adolescents.
The Italian Medicines Agency (AIFA) has granted approval to conduct human clinical trials on raloxifene, a generic osteoporosis drug to…
Primary care physicians are qualified to offer care for a comprehensive scope of conditions in their patient population. They maintain…
Merck (MSD) has collaborated with contract research services company IRBM for the identification and development of new peptide therapeutics that…
Scientists at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy have claimed that a vaccine candidate could neutralise coronavirus…
Italian pharmaceutical and diagnostics company Menarini Group has signed a definitive agreement to acquire US-based Stemline Therapeutics for up to…
Thank you for subscribing to Pharmaceutical Technology